Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus

Evaluation of Janus Kinase_3 Expression in Juvenile Onset Systemic Lupus Erythematosus

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04293510

Enrollment

Registered

2020-03-03

Start date

2020-07-15

Completion date

2022-07-15

Last updated

2020-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Keywords

Janus-kinase3, active, lupus

Brief summary

One of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and transcriptional factors such as signal transducers and activators of transcription (STATs). For immune mediated diseases, both activating and inactivating mutations of JAKs and STATs may cause abnormalities in immune homeostasis. Polymorphisms of JAK/STAT genes have been linked to susceptibility for rheumatoid arthritis (RA) , systemic lupus erythematosus (SLE), psoriatic arthritis (PA) and inflammatory bowel disease (IBD) . Janus\_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients during active stage of the disease through this study

Detailed description

Investigators will assess the relationship between the expression of Janus\_kinase 3 and the clinical and laboratory parameters of disease activity . Disease activity will be assessed through the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Also, investigators will evaluate the relationship between Janus\_ kinase 3 expression and histopathological classes of lupus nephritis according to the 2003 International Society of Nephrology/ Renal Pathology Society (ISN/RPS) classification of lupus nephritis. This will be done through Janus\_kinase 3 assessment in the blood and renal tissue of lupus patients.

Interventions

PROCEDURErenal biopsy and blood sampling

renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

7 Years to 16 Years

Inclusion criteria

* Age younger than 16 years. * Active disease stage * Patients with biopsy proven lupus nephritis according to ISN/RPS classification criteria of lupus nephritis

Exclusion criteria

* Lupus patients in remission. * Lupus patients with end stage renal disease. * Lupus patients with secondary thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). * patients with moderate or severe infection

Design outcomes

Primary

Measure	Time frame	Description
Janus-kinase 3 expression	within 2 years	evaluation of Janus-kinase 3 expression in blood and renal tissue of lupus patients during active stage of disease

Secondary

Measure	Time frame	Description
correlation	2 years	relationship between Janus- kinase expression and clinical and laboratory parameters of disease activity

Other

Measure	Time frame	Description
correlation	2 years	relationship between Janus-kinase 3 expression and histopathological classification of renal biopsy in lupus nephritis proven patients

Contacts

Primary ContactEnas Mohamed Sayed Ahmed

enasmhmd05@gmail.com01004870406

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026